Visual Abstract

In PWD2 inadequately controlled with GLP-1 RA therapy, addition of basal insulin is recommended. We used a US electronic medical record data source (IBM Explorys) of ~4 million PWD2 to assess the real-world impact of adding the basal insulin analog Gla-300 to GLP-1RA therapy in PWD2. Insulin-naïve PWD2 receiving GLP1-RAs who subsequently received Gla-300 between Mar 1, 2015-Sep 30, 2019 were identified; patients were required to have data for ≥12 months prior, and ≥6-month after, addition of Gla-300. Mean age of participants (N=271) was 57.9 (SD: 10.8) years. Baseline HbA1c was 9.16%, and was significantly reduced (0.97 [SD:1.60], p<0.0001) after addition of Gla-300; a significant increase in proportion of PWD2 achieving HbA1c control was observed after addition of Gla-300 (HbA1c <7.0%: 4.80% vs. 22.14%, p<0.0001; HbA1c <8.0%: 19.56% vs. 51.29%, p<0.0001). Incidence of overall (8.49% vs. 9.59%, p=0.513), and inpatient/emergency room-associated hypoglycemia (0.37% vs. 0.74%, p=1.000), as well as overall (0.33 vs. 0.46 PPPY, p=0.170) and inpatient/emergency room-associated hypoglycemia events (0.01 vs. 0.04 PPPY, p=0.466) were similar before and after addition of Gla-300. In US RW clinical practice, adding Gla-300 to GLP-1 RA significantly improved glycemic control without significantly increasing hypoglycemia.

graphic
View largeDownload slide
Disclosure

T. S. Bailey: Consultant; Self; Abbott Diabetes, LifeScan, Novo Nordisk, Sanofi, Research Support; Self; Abbott, Abbott Diabetes, Biolinq, Capillary Biomedical, Inc., Dexcom, Inc., Eli Lilly and Company, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc., Livongo, Medtronic, Medtrum Technologies, Novo Nordisk, REMD Biotherapeutics, Sanofi, Sanvita, Viacyte, Inc., vTv Therapeutics, Zealand Pharma A/S, Speaker’s Bureau; Self; BD, Medtronic, Sanofi. J. Westerbacka: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. C. Nicholls: Employee; Self; Sanofi. J. Gill: Employee; Self; Sanofi US, Other Relationship; Self; American Diabetes Association, Stock/Shareholder; Self; Sanofi US. M. Jones s: None. L. Shenoy: None.

Funding

Sanofi

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.